One-fourth of the patients who receive androgen-targeted therapy may relapse with tumors that show features of neuroendocrine prostate cancer and develop treatment-resistant disease, according to published research.
from Medindia Health News https://ift.tt/2NMF8Ki
No comments:
Post a Comment